Peptide vaccines against cancer are described herein. In particular, the present invention describes epitope peptides derived from IQGAP3 that elicit CTLs. The present invention also provides established CTLs that specifically recognize HLA-A24 or HLA-A02 positive target cells pulsed with the peptides. Antigen-presenting cells and exosomes that present any of the peptides, as well as methods for inducing antigen-presenting cells are also provided. The present invention further provides pharmaceutical agents containing the IQGAP3 polypeptides or polynucleotides encoding thereof, as well as exosomes and antigen-presenting cells as active ingredients. Furthermore, the present invention provides methods for treating and/or prophylaxis of (i.e., preventing) cancers (tumors), and/or prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the IQGAP3 polypeptides, polynucleotides encoding the polypeptides, exosomes or antigen-presenting cells presenting the polypeptides, or the pharmaceutical agents of the present invention. The cancers to be targeted include, but are not limited to, renal, esophageal, gastric, lung, breast, bladder and pancreatic cancer.La présente invention concerne des vaccins peptidiques contre le cancer. En particulier, la présente invention concerne des peptides épitopes dérivés de IQGAP3 qui élicitent les cellules T cytotoxiques (CTL). La présente invention concerne également des CTL établis qui reconnaissent spécifiquement les cellules cibles HLA-A24 ou HLA-A02 positives pulsées avec les peptides. L’invention concerne également des cellules présentant l’antigène et des exosomes qui présentent l’un quelconque des peptides, ainsi que des méthodes d’induction de cellules présentant l’antigène. La présente invention concerne en outre des agents pharmaceutiques contenant les polypeptides dérivés d’IQGAP3 ou des polynucléotides codant pour ceux-ci, ainsi que des exosomes et des
